Thus, MS patients in the early course, who are presumed to have high inflammatory disease activity, may tend to show a suboptimal response to fingolimod 0.5 mg once daily because of an insufficient decrease in CD4+TCM cells. The gene discussed is CD4; the disease is myeloid sarcoma.